Published in:
01-12-2011 | Original Article
Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital
Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2011
Login to get accessAbstract
Purpose
We report on our experience in terms of eligibility, safety, response and survival for treatment of hepatocellular carcinoma (HCC) with 90Y microspheres. Secondly, we investigated the urinary excretion of 90Y following treatment.
Methods
We retrospectively reviewed all HCC patients referred to our department for 90Y microsphere treatment. We recorded reasons for not proceeding to actual treatment. In case treatment was performed, we assessed the tolerance (Common Terminology Criteria for Adverse Events v3.0, CTCAE v3.0), the response [modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria] and long-term survival (Kaplan-Meier). The urinary excretion was estimated by 12-h urine collections post-injection for analysis in a gamma counter.
Results
Forty-three HCC patients were referred for radioembolization. Fourteen patients were excluded, mainly due to unfavourable 99mTc-macroaggregated albumin (MAA) distribution. Twenty-nine patients were treated with 90Y microspheres (TheraSphere, mean activity 2.17 GBq). In four patients severe clinical adverse events were encountered, however only in one case clearly related to the therapy. Twenty patients were assessable by mRECIST: complete response in 15%, partial response in 35%, stable disease in 30% and progression in 20% were observed. A median survival of 12.3 months (95% confidence interval 9.4–15.2) was estimated. Concerning the substudy on urinary excretion, only 0.0025% of the administered activity was excreted in the urine within the first 12 h following TheraSphere.
Conclusion
Following a strict workup before admitting patients to radioembolization with TheraSphere, we found good clinical tolerance in the vast majority of patients. Radiological response assessment yielded an overall response rate of 50%, when evaluated early following treatment. Urine analysis showed consistently only low activities of 90Y excreted in the urine.